Suicide completion rates are significantly higher in males than females in most societies. Although gender differences in suicide rates have been partially explained by environmental and behavioral factors, it is possible that genetic factors, through differential expression between genders, may also help explain gender moderation of suicide risk. This study investigated X-linked genes in suicide completers using a two-step strategy. We first took advantage of the genetic structure of the French-Canadian population and genotyped 722 unrelated French-Canadian male subjects, of whom 333 were suicide completers and 389 were non-suicide controls, using a panel of 37 microsatellite markers spanning the entire X chromosome. Nine haplotype windows and several individual markers were associated with suicide. Significant results aggregated primarily in two regions, one in the long arm and another in the short arm of chromosome X, limited by markers DXS8051 and DXS8102, and DXS1001 and DXS8106, respectively. The second stage of the study investigated differential brain expression of genes mapping to associated regions in Brodmann areas 8/9, 11, 44 and 46, in an independent sample of suicide completers and controls. Six genes within these regions, Rho GTPase-activating protein 6, adaptor-related protein complex 1 sigma 2 subunit, glycoprotein M6B, ribosomal protein S6 kinase 90 kDa polypeptide 3, spermidine/spermine N(1)-acetyltransferase 1 and THO complex 2, were found to be differentially expressed in suicide completers.
Introduction
Suicide is a major public health problem and is one of the leading causes of death in Western countries. 1 Although a history of psychiatric disorders is detected in the majority of suicide completers, transmission of psychopathology seems to be independent of suicide, 2 supporting the concept that suicidal behavior is a distinct phenotype. There is a significant amount of evidence to support a genetic component to suicidal behavior, as evidenced by twin, 3 adoption 4,5 and family studies. 2 A few linkage studies have been conducted investigating loci segregating with suicide completion, suicide attempt and suicidal ideation. In a sample of alcoholdependent and control subjects, regions in chromosomes 1, 2 and 3 were linked with suicide attempts (chromosome 2) or suicidality (chromosomes 1 and 3). 6 Using probands with recurrent, early-onset, major depressive disorder, a number of chromosomal regions were linked with suicide attempts, including 2p, 5q, 6q, 8p, 11q and Xq. 7 In this study, the regions with the two highest logarithm of the odds scores were 8p22-p21 and Xq25-26.1, in affected relative pairs with depression spectrum disorder, and recurrent, early-onset, major depressive disorder, respectively. A third study, carried out in a large bipolar pedigree, identified regions linked with either suicide completions (2q, 4p, 6q) or suicide attempts (10q). 8 Suicidal behavior has remarkably different distribution between genders (reviewed in Hawton 9 ). These differences have been attributed to a number of different factors, including the use of higher lethality methods by male suicide victims, as well as differences in comorbid Axis I and Axis II diagnoses. [10] [11] [12] In addition, both risk and protective factors vary between genders. 13 It is possible that genetic factors, through differential expression between the genders, may also help explain gender moderation of suicide risk. Exploring this rationale, candidate gene studies have identified a number of genes with genderspecific effects related to suicidal behaviors, including catechol-O-methyltransferase, 14, 15 the serotonin transporter (5-HTT), 16 cholecystokinin 17 and monoamine oxidase A (MAO-A). 18 MAO-A is particularly interesting as it is located on the X chromosome, and genetic variants have been associated with impulsivity, aggression and antisocial behavior, 19, 20 each of which are risk factors for suicide.
As males are hemizygous for genes on the X chromosome, loci that map to this chromosome are an important source of potential variability, and are thus of interest to the investigation of genetic factors that could moderate gender differences in suicidal behavior. In this study, we chose to carry out a two-stage case-control study investigating X-linked markers in a sample of suicide completers and controls. The first stage comprised an association study using markers spanning the X chromosome. This stage took advantage of the genetic structure of the French-Canadian population, which is a young (12 generations) population that remained isolated until very recently because of cultural and religious reasons, leading to a founder effect confirmed by many studies. For instance, among individuals affected by oculopharyngeal muscular dystrophy (OPMD), a disease caused by a gene on chromosome 14, unrelated FrenchCanadian OPMD patients shared 75% of alleles for a 5-cM interval. 21, 22 Similar results were observed for other diseases. 23 As B70% of the gene pool of this FrenchCanadian population derives from an initial group of 3380 founders, it is reasonable to hypothesize that there is reduced variability in genetic factors that may be etiologically related to suicide among French Canadians. Taken together, this means that by testing FrenchCanadian suicide completers, it is possible to detect ancestral predisposing variants by typing markers within an average interval of 5 cM.
The second stage consisted of investigating genes mapping to associated regions by studying their differential pattern of expression in the brain in a sample of suicide completers and controls.
Methods

Subjects
Genetic association study. We investigated a total of 722 unrelated French-Canadian male subjects, as shown in Table 1a . Cases for this study were 333 individuals who died by suicide (S), as assessed by the Quebec Coroner's office. We also included 389 subjects who did not die by suicide (NS), which comprised both living (311) and deceased (78) individuals. These subjects were recruited from outpatient clinics or from the Quebec general population. Psychiatric diagnoses were assessed using the Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-IV Axis I (SCID-I) 24 or the Diagnostic Interview Schedule using DSM-III-R criteria. 25 When possible, interviewees were the subjects themselves; in other cases, the psychological autopsy method was used with the informant best acquainted with the subject. As major depressive disorder is the most common Axis I disorder among suicide completers, 10 we selected our non-suicide control group to include a high percentage of subjects with depressive disorders. We classified subjects as being among the depressive disorders group when they had either a present or lifetime diagnosis of major depression, dysthymic disorder or depressive disorders not otherwise specified. Informed consent was obtained from either the subject or from his next of kin, as appropriate.
Gene expression study. An independent sample of French-Canadian male subjects was used to assess gene expression. Brain samples from Brodmann area (BA) 8/9 (dorsolateral prefrontal cortex (DLPFC)), BA 11 (orbital cortex), BA 44 (inferior frontal gyrus) and BA 46 (DLPFC) were obtained from the Quebec Suicide Brain Bank (QSBB) (www.douglasrecherche. qc.ca/suicide). These regions were selected due to evidence for their involvement in suicide and major depression. 26 Brain tissues were processed and dissected at 4 1C, and snap-frozen in liquid nitrogen before storage at À80 1C, following standard procedures. 27 All subjects collected by the QSBB died suddenly without a prolonged agonal period. Brain Table 1 Characteristics of case and control subjects used for (a) genotyping study and (b) gene expression study tissues were dissected in accordance with standard neuroanatomical definitions. 28 All subjects were characterized by the psychological autopsy method using structured diagnostic methods eliciting Axis I diagnoses according to the DSM-IV criteria, as detailed elsewhere. 29 Diagnostic information is shown in Table 1b . The sample consisted of 14 depressed suicide completers who died during an episode of major depression, 8 suicide completers with no history of major depression, and 13 controls with no history of suicidal behavior. These subjects had an average age of 35.6 with an average post-mortem interval of 25 h. There were no significant differences between the groups for either of these variables. This study was approved by our local institutional review board.
Genotyping
Genomic DNA was extracted from blood or saliva using standard procedures. 30 A total of 37 microsatellite markers were genotyped, with an average intermarker distance of 5.7 cM (0.0-11.1 cM). Markers were obtained from the ABI Prism Linkage Mapping Set 2.5 and were analyzed using the ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Genotypes were assessed using GeneMapper 3.7 (Applied Biosystems).
Statistical analysis
The likelihood ratio w 2 -test statistic was used to identify differences in allele or haplotype frequencies between cases and controls. These association tests were computed using the UNPHASED (version 3.0) suite of software for case-control data 31 and were carried out for both single markers as well as marker pairs using a sliding window approach. To control for the presence of depressive disorders, these analyses were also carried out with depressive disorders (present, absent, unknown) added as a covariate. As the number of subjects with other Axis I diagnoses was small, their effects were not assessed. Alleles with frequencies < 0.05 in the entire sample were pooled to reduce the effects of rare alleles. All tests of significance were two-sided at the level of Pp0.05. Corrections for multiple testing were not carried out. Linkage disequilibrium was assessed using the LDMAX algorithm of the Graphical Overview of Linkage Disequilibrium (GOLD) program. 32 
Microarray analysis
The RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). RNA samples used for analysis possessed A260/A280 > 1.9 and 28S/18S rRNA peak height ratios > 1.6. Samples were analyzed using the Human Genome U133 A/B set, which comprises two GeneChip arrays with 45 000 probe sets, representing B33 000 human genes (http://www.affymetrix.com).
GeneChip analysis was carried out with Microarray Analysis Suite version 5.0 (MAS 5), Data Mining Tool 2.0. All the genes represented on the GeneChip were globally normalized and scaled to a signal intensity of 100. RNA quality indicators used to pre-filter samples before analysis included b-actin 5 0 /3 0 ratio, glyceraldehyde-3-phosphate dehydrogenase 5 0 /3 0 ratio, RawQ (noise), scale factor and percentage of 'present' calls per array. Outlier subjects were excluded in regions where they did not pass quality standards, such that different numbers of subjects were included in the final analysis across the four regions (for BA 8/ 9: 7 control (C), 5 non-depressed suicide (NDS) and 11 depressed suicide (DS); for BA 11: 7 C, 5 NDS and 11 DS; for BA 44: 12 C, 6 NDS and 13 DS; and for BA 46: 7 C, 7 NDS and 12 DS).
Data analysis
Gene expression data were analyzed using Genesis (GeneLogic, Gaithersburg, MD, USA) and AVADIS software (Strand Genomics, Redwood City, CA, USA). Gene expression values were log 2-transformed, then Student's t-tests were carried out for each probe set for contrasts of DS vs NDS, DS vs C, and NDS vs C. Genes selected for further analysis had to show, in at least two brain regions, a P-value fold change combination of Pp0.01 and fold change of at least ± 1.3. In addition, genes in which all significant probe sets had a present call of < 75% were not included.
Reverse transcriptase PCR validation
Total RNA for each brain region was extracted from frozen tissue using an RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia, CA, USA). RNA quality was measured using an Agilent 2100 Bioanalyzer (Agilent Technologies), and only samples with an RNA integrity number > 5 were included. cDNA synthesis was carried out using oligo(dT) priming (Invitrogen, Carlsbad, CA, USA).
The PCR reactions used 100 ng of cDNA template in a 20 ml reaction volume, and were run on 2% agarose gels. Primer sequences are shown in Supplementary  Table 1 . Fold change and P-values between groups were evaluated using relative quantitation with glyceraldehyde-3-phosphate dehydrogenase as an endogenous control. All reactions were carried out in triplicate. Semiquantitative results were analyzed with GeneTools v3.06 (SynGene, Cambridge, UK), with automatic computation of gene and control band densitometry. One-tailed Student's t-tests were carried out (Statistical Package for Social Sciences (SPSS); version 15.0; SPSS Inc., Chicago, IL, USA).
Results
A total of 722 subjects were genotyped at thirty-seven microsatellite markers to identify the loci associated with completed suicide. There was an average genetic distance between contiguous markers of 5.7 cM. Alleles with frequencies < 0.05 were pooled into a single allele. Before pooling infrequent alleles, the average marker heterozygosity was 0.71.
The w 2 analyses revealed five markers that were significantly associated with completed suicide. To identify haplotypes associated with suicide completion, a sliding window approach was used for each pair of markers. Nine haplotype windows were found to be associated with suicide. Results from both sets of analysis are shown in Figure 1a . For both analyses, the most significant findings were obtained with markers DXS1001 and DXS8106, (P = 0.001 and 0.0003, respectively), both of which survive correction for multiple testing. Seven of the marker pairs encompassed single markers, which were significant or near significant, of which the pair DXS1227-DXS8106 survives correction for multiple testing.
Score tests were used to assess the effects of individual alleles for each significant marker and marker pair. These results are depicted in Tables 2a  and b . For marker DXS984, the most significant allele represents the pooled alleles. Before pooling at this locus, the P-value was 0.034, and the strongest associations were observed with alleles 176 and 188, although these did not reach nominal statistical significance (P-values of 0.078 and 0.057, respectively).
Both protective and susceptibility alleles were observed at the majority of markers and marker pairs. For both DXS1001 and DXS8106, the most significantly associated allele at each locus conferred a susceptibility to suicide. The most strongly protective allele was also found at DXS1001. Among the marker pairs, the strongest association was found with DXS1227-DXS8106, with the most significant haplotype being found with a frequency eight times higher among suicide completers.
As risk factors for suicide completion may differ among Axis I disorders, we repeated the analyses while controlling for a history of depressive disorders, the most common diagnostic category associated with suicide. 10 When this was carried out, marker DXS8051, and pairs DXS1106-DXS8088 and DXS8091-DXS8069 lost significance (P = 0.070, 0.066 and 0.082, respectively). To further characterize this effect, and to identify regions that may be specific to suicide completions in the context of depressive disorders, these analyses were carried out using only depressed suicides and depressed controls (N = 302). These results are depicted in Figure 1b and Tables 3a  and b . Although a number of regions are identical or adjacent (DXS1224 and the pair DXS1060-DXS8051) to those found in the entire sample, an additional region was found with marker DXS8102 and nearby marker pairs DXS1214-DXS8102 and DXS8090-DXS1068. The intervening pair (DXS8102-DXS8090) also showed a near-significant association (P = 0.092). In addition, a number of markers found to be associated with suicide in the entire sample were no longer significant in the subset of subjects with depressive disorders (DXS8051, DXS1047 and DXS984). The strongest associations were found with DXS1224, DXS8106 and DSX1224-DXS8019, each of which survive corrections for multiple testing.
To further characterize the regions showing evidence of involvement in suicide, and to confirm that our use of uncorrected statistical tests identified truly associated regions, we investigated the differential expression of genes mapping to these regions by means of microarray analyses in brain tissues obtained from an independent sample of FrenchCanadian males who died by suicide as compared with French-Canadian males who died suddenly by other causes. Analyses were carried out in four cortical brain regions, BA 8/9, 11, 44 and 46, which are believed to be involved in the neurobiology of suicide and major depressive disorder. 26 On the basis of results from both the entire sample and subset depressed subjects, we focused on two X-chromosomal regions: between DXS8051 (Xp22.2) and DXS8102 (Xp11.4) (34.1 cM), and between DXS1001 (Xq24) and DXS8106 (Xq27.3) (34.2 cM). These two regions contain 131 and 121 annotated genes, respectively. To minimize false positive findings, we focused on genes that were differentially expressed within at least one of the comparisons in at least two brain regions. A total of eight genes fulfilled these criteria and are shown in Table 4 and Supplementary Table 1 .
We subsequently proceeded to the validation of these eight differentially expressed genes. Our group has been working on spermidine/spermine N(1)-acetyltransferase 1 (SAT1) gene because of results that independently pointed to this gene as important in suicide/major depressive disorder, and the validation and investigation of its differential expression in these regions has previously been performed by our group. 33, 34 Of the remaining genes, Rho GTPase activating protein 6 (ARHGAP6), glycoprotein M6B (GPM6B), adaptor-related protein complex 1 sigma 2 subunit (AP1S2), ribosomal protein S6 kinase 90 kDa polypeptide 3 (RPS6KA3) and THO complex 2 (THOC2) validated for several of the comparisons that were significant from microarray analysis. The expression of ARHGAP6 in BA44, and AP1S2 in BA8/ 9 were significantly different for the comparisons of interest, but the fold changes were in the opposite direction than those observed from microarray experiments. The reason for this is not clear.
Both stromal antigen 2 and X-linked RNA-binding motif protein (RBMX) failed to validate. When examined further, it seems that the RBMX probe set 225310_at is located within an exonic region, which has only been observed in a processed transcript (RBMX-004, OTTHUMT00000058510). As the primers we used for validation do not bind to this transcript, this may partially explain the failure of this gene to validate.
Discussion
We conducted a two-stage investigation of X-chromosome loci in suicide completion using a sample of male French-Canadian subjects. We first identified a number of chromosomal regions that showed association to suicide, and subsequently studied patterns of differential expression in the brain for several genes that map within these regions.
This study identified five markers, DXS8051, DXS1001, DXS1047, DXS984 and DXS8106, which were significantly associated with completed suicide in the entire sample. The two strongest associations were obtained with DXS1001 and DXS8106, which are localized to Xq24 and Xq27.3, respectively. Nine marker pairs were also found to be significant, of which the strongest signals were seen in Xp22, Xq24 and Xq27. When suicide was examined in the context of depression, several other markers were found to be significant, producing a peak spanning a 10-Mb region from Xp21.2 to Xp11.4. In addition, several markers that were significant in the entire sample were not significant in the depressed subgroup, which may indicate that these peaks were related to other comorbid conditions. Alternatively, this may simply be a consequence of reduced power in the smaller sample. Overall, markers DXS1001 and DXS8106, as well as pairs DXS1224-DXS8019, DXS1001-DXS8009, DXS1227-DXS8106 and DXS8106-DXS8043, were significant in both analyses.
The identification of DXS1047, found in Xq25, as being associated with suicide is in partial agreement with results from a previous linkage study that showed significant findings for this marker in the context of suicide among families with recurrent, early-onset, depressive disorders. 7 It is thus interesting that in our study this marker was not significant in the depressed sample. DXS1047 has also been associated with bipolar disorder, 35, 36 and both this marker and DXS1001 have been associated with autism. 37, 38 In addition, DXS1001 is closely linked with the glutamate receptor subunit 3 gene at Xq25, X chromosome and suicide LM Fiori et al which has been associated with a number of psychiatric conditions including bipolar disorder, schizophrenia and citalopram treatment-emergent suicidal ideation. [39] [40] [41] [42] In the second stage of our study, we focused our efforts on identifying genes within our associated regions that show differential expression in the brains of suicide completers. Using microarray expression data from BA 8/9, 11, 44 and 46, six genes were identified, which were differentially expressed in suicide completers in at least two brain regions.
One of the genes identified in this study, SAT1, was previously identified by our group to be significantly downregulated in a number of different brain regions in suicide completers, and identified a promoter single-nucleotide polymorphism, rs6926342, which was associated with suicide completion and expression of SAT1 in the brain. 33, 34, 43, 44 This gene is involved in polyamine catabolism, and the polyamine system has been implicated in a number of psychiatric conditions, including suicide. 45 The remaining five genes also showed decreased expression in suicide completers. Interestingly, RPS6KA3 showed region-specific alterations in expression, with increased expression in depressed compared with nondepressed suicides in BA 8/9, and decreased expression in BA 44. This gene, which is involved in cognitive function and brain development, 46 ,47 has been implicated in several forms of Xlinked mental retardation (XLMR) resulting from both duplications and mutations. [47] [48] [49] [50] [51] This suggests that dysregulation in the expression of this gene in either direction can have profound effects, and may explain our findings of both increased and decreased levels. AP1S2 has also been implicated in XLMR, [52] [53] [54] and behavioral effects resulting from mutations are theorized to be due to brain-specific defects in intracellular protein trafficking. 54 Dysregulation of ARHGAP6 and GPM6B in suicide completers is also of interest as both these genes are involved in neuronal function. Indeed, ARHGAP6 has been found to be upregulated during neurogenesis, 55 whereas GPM6B is involved in myelination and is upregulated in the brain during terminal neuronal differentiation and myelination. [56] [57] [58] Our findings of decreased expression of these two genes may indicate alterations in neuronal functioning or in numbers of the neurons themselves.
One of the aims of this study was to identify genetic factors that may explain the gender moderation of suicide risk. In this light, it is of interest that two of the genes showing downregulation in our suicide completers, GPM6B and AP1S2, have also been shown to escape X inactivation and show increased expression in females. [59] [60] [61] This may thus indicate that elevated levels of these genes may be protective against suicide in females. In addition, as males are hemizygous for the majority of genes on the X chromosome, they are also more susceptible to the effects of genetic variations, which may alter the function or expression of genes. Indeed, as mentioned above, a promoter variant influencing the expression of SAT1 has already been identified, 33 and it could be speculated that heterozygous females possessing the risk allele may be less affected than hemizygous males.
Although the majority of genes on the X chromosome do not escape inactivation in females, 59 and therefore, may not be responsible for gender differences in suicide rates, the X chromosome remains of significant interest for investigation of genes related to psychiatric phenotypes. It has been noted that the X chromosome possesses a disproportionately high number of genes associated with mental function, including intelligence, social cognition and emotional regulation. 62 Therefore, it is not surprizing that numerous studies have identified and suicide. 7 Our findings of multiple X-linked loci associated with suicide provide additional evidence suggesting that genes mapping to the X chromosome may be important in complex behavioral phenotypes.
Our use of a sample comprised entirely of FrenchCanadian subjects allowed us to use a genetic strategy to detect suicide-related loci that would not have been possible in samples from admixed populations, in which linkage disequilibrium with predisposing genes would have been much lower. The FrenchCanadian population was established relatively recently and the majority of individuals are descendents of B7000 individuals who immigrated to Quebec from France before 1760, and who, until recently, have remained relatively isolated from other populations. 23 The existence of a founder effect in this population has been well documented, [21] [22] [23] 70 and the high level of genetic homogeneity has allowed the detection of predisposing ancestral variants by typing markers within relatively small intervals. The power to detect these predisposing variants decreases with increased genetic variability resulting from the introduction of other predisposing variants within a single gene and in other predisposing genes. However, our use of a relatively large sample and a complementary design to follow up on positive findings circumvented these problems.
There are a number of limitations to this study. As this study was carried out exclusively in French Canadians, it is possible that the associations obtained in this sample may not be found in other populations. In addition, psychiatric information was not available for all subjects, which limited our ability to examine suicide in the context of other Axis I disorders. Then, we chose not to correct our association tests for multiple testing, which may have increased the likelihood of false-positive findings. However, our findings of differentially expressed genes within these chromosomal regions served as a confirmation of the association of these loci with suicide completion in spite of our lack of correction. Finally, it is possible that the genes identified in this study are not those responsible for the association peaks, and that the causal genes remain to be identified. Indeed, it is likely that additional genes are involved as we only validated one gene, THOC2, in the Xq region examined, despite this region showing markers with stronger associations to suicide.
In summary, we present results showing a number of regions on the X chromosome that are associated with suicide completion, and identified six genes in these regions that show differential expression in suicide completers. These results highlight the importance of the X chromosome in suicidal behavior, and expand our knowledge of the pathways involved in this complex trait.
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